Pancragen
One of the Khavinson "bioregulator" peptides from Russian aging research, marketed for the pancreas. Evidence comes mainly from Russian cell and animal studies.
Sold as a supplement in Russia; not approved in the US. Research use only.
Look it up on Wikipedia14 listings across 13 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Andy Peps Studio #64 by metascore · China |
PA20 Pancragen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Baohua Dongnuo Biotechnology BHD #77 by metascore · China |
PA20 Pancragen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
LN Peptides #254 by metascore · China |
Metascore 71Finnrick 72%Bought vials 99% of label · 39 testsTitrateLabNo report for thisOnline checkout |
PA20 Pancragen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy |
BeiBangAn #28 by metascore · China |
PA20 Pancragen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Uther #62 by metascore · China |
Metascore 79Finnrick 64%Bought vials 105% of label · 73 testsTitrateLabNo report for thisOnline checkout |
Pancragen 20mg (10 Vials / Kit) | 10 × 20 mg = 200 mg | $150.00 $15.00 per vial |
$0.750 | Buy |
Qingdao Sigma Chemical QSC #69 by metascore |
Pancragen 20mg | 20-Vial Kit | Pancreatic Tissue Bioregulator | 20 × 20 mg = 400 mg | $470.00 $23.50 per vial |
$1.18 | Buy | |
Qingdao Sigma Chemical QSC #69 by metascore |
Pancragen 20mg | 10-Vial Kit | Pancreatic Tissue Bioregulator | 10 × 20 mg = 200 mg | $260.00 $26.00 per vial |
$1.30 | Buy | |
Peptidology #5 by metascore · US, AZ 85254 |
Metascore 87Finnrick 71%Bought vials 97% of label · 18 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisConfirmed with lab: 34 of 34Online checkout |
Pancragen 23 mg (23mg) | 1 × 23 mg | $47.19 | $2.05 | Buy |
Eros Peptides #129 by metascore · US, GA 30339 |
Metascore 74 medium confidenceFinnrick 77%Bought vials 110% of label · 3 testsTitrateLab · Peptide CriticLab report (image)Online checkout |
Pancragen 20MG | 1 × 20 mg | $50.99 | $2.55 | Buy |
Liberty Peptides #63 by metascore · US, DE 19801 |
Metascore 79Finnrick 53%Bought vials 107% of label · 18 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Pancragen (20mg) | 1 × 20 mg | $55.00 | $2.75 | Buy |
Core Peptides #282 by metascore |
Metascore 70 medium confidenceFinnrick 76%PepIndex 24/100Bought vials 92% of label · 4 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisOnline checkout |
Pancragen – 20MG | 1 × 20 mg | $63.00 | $3.15 | Buy |
Amino Asylum #245 by metascore |
Metascore 71Finnrick 62%PepIndex 26/100Bought vials 100% of label · 15 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Pancragen 20MG | 1 × 20 mg | $64.99 | $3.25 | Buy |
Biolongevity Labs #166 by metascore · US, Akron, OH 44321 |
Metascore 73Finnrick 71%PepIndex 58/100Bought vials 102% of label · 34 testsTitrateLab · Peptide CriticNo report for thisOnline checkout |
Pancragen (20mg) | 1 × 20 mg | $94.97 | $4.75 | Buy |
Certified Peptides #66 by metascore · US, WA 98579 |
Metascore 79Finnrick 58%Bought vials 100% of label · 12 testsTitrateLabNo report for thisOnline checkout |
PANCRAGEN 20MG | 1 × 20 mg | $105.00 | $5.25 | Buy |
Mixing a 20 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2,000 mcg | 200 mcg |
| 2 mL | 10 mg/mL | 1,000 mcg | 100 mcg |
| 3 mL | 6.667 mg/mL | 666.7 mcg | 66.67 mcg |
| 5 mL | 4 mg/mL | 400 mcg | 40 mcg |
Published lab results
2 certificates of analysis that vendors publish for Pancragen. Numbers are only filled in where the document is readable text; image-only COAs are linked without numbers. A vendor's own COA shows one tested sample, not every batch.
| Vendor | Lab | Date | Label | Measured | Purity | Batch | |
|---|---|---|---|---|---|---|---|
Eros PeptidesCOA note |
Janoshik | – | 20 mg | – | – | View (image) | |
Peptides 4 Research |
– | – | 20 mg | – | – | 260305PC203 | View (image) |
Doses studied in research Animal or lab studies only
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
Animal studies: Old female rhesus monkeys received 0.05 mg (50 mcg) per animal per day intramuscularly for 10 days (PMIDs 28509500, 25946840); diabetic rats received it by mouth or intramuscularly (dose not stated); tissue cultures used 0.05 ng/ml.
Not an approved drug. One small, non-randomized report in 33 elderly people with type 2 diabetes (PMID 22448364) described lower glucose and insulin after pancragen but does not state the dose, route or duration in its abstract. Doses in animal studies do not translate directly to people.
What the research says
Pancragen (the tetrapeptide Lys-Glu-Asp-Trp) has been studied almost entirely by one Russian research group, mostly in rats, aged monkeys and cell culture, where it lowers blood glucose and stimulates pancreatic cell markers. The only human report is a small non-randomized, non-placebo-controlled study in elderly people with type 2 diabetes; no independent or randomized human data were found.
Key papers ✓ 9? 1
-
Prospects of using pancragen for correction of metabolic disorders in elderly people.Humanssize not reportedNo control groupComparison of healthy vs diabetic older persons, with pancragen given to patients with type 2 diabetes versus patients not receiving it
In 33 elderly people with type 2 diabetes and 30 healthy elderly controls, pancragen lowered fasting and post-load glucose, insulin and the insulin resistance index, while untreated participants showed no change; the study was not randomized or placebo-controlled.
Key resultNocturnal melatonin production was reduced by 70% in type 2 diabetes vs healthy individuals; pancragen significantly decreased fasting and glucose-tolerance-test glucose and reduced insulin and insulin resistance index
Study details
- Studied
- Older persons: 30 healthy and 33 with type 2 diabetes
- Main outcome
- Fasting glucose, glucose tolerance test, insulin and insulin resistance index
- Sample
- 30 healthy older persons and 33 patients with type 2 diabetes
- Authors' conclusion
- Pancragen is a promising approach to correct insulin resistance in elderly individuals.
- Limitations
- Abstract gives no randomization, blinding, dose or duration details.
-
[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].Animals9 animals10 daysComparative animal study against glimepiride
In 9 old rhesus monkeys, 10 days of pancragen lowered fasting glucose and normalized insulin and C-peptide responses, while the comparator glimepiride produced a larger and more delayed glucose fall.
Study details
- Studied
- Old (20-25 years) clinically healthy female rhesus monkeys
- Compared with
- Glimepiride 4 mg/animal per day orally
- Main outcome
- Blood glucose, insulin and C peptide, basal and during glucose tolerance testing
- Sample
- 9 old female rhesus monkeys (5 pancragen, 4 glimepiride)
- Authors' conclusion
- Pancragen lowered basal glucose and normalized insulin and C peptide; the authors suggest it is effective and safe for age-related pancreatic endocrine imbalance.
- Limitations
- Small study in healthy monkeys; 4-5 animals per group.
-
[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].Animalssize not reported10 days of treatment; effect followed for 3 weeks after discontinuationGlucose tolerance test before and after pancragen
In old female rhesus monkeys, 10 days of pancragen increased the rate of glucose disappearance and normalized insulin and C-peptide dynamics, with partial persistence 3 weeks after stopping.
Study details
- Studied
- Old female rhesus monkeys compared with young animals
- Compared with
- Young animals / control period
- Main outcome
- Glucose disappearance rate, insulin and C-peptide dynamics
- Sample
- Old female rhesus monkeys; number not stated
- Authors' conclusion
- Pancragen increased glucose disappearance rate and normalized insulin and C-peptide responses; the effect partially persisted 3 weeks after stopping. Authors call it promising for age-related endocrine dysfunction.
- Limitations
- Animal study; sample size not given in abstract.
-
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.Animalssize not reportedExperimental diabetes model
In rats with streptozotocin-induced diabetes, oral pancragen lowered blood glucose and intramuscular pancragen normalized mesenteric capillary endothelial adhesion but did not change capillary permeability.
Study details
- Studied
- Wistar rats with streptozotocin-induced diabetes
- Main outcome
- Blood glucose, mesenteric capillary permeability and adhesion
- Authors' conclusion
- Oral pancragen had a pronounced hypoglycemic effect and intramuscular pancragen normalized capillary endothelium adhesion but not permeability, indicating homeostatic and endothelioprotective effects early in diabetes.
- Limitations
- Animal study; sample size not given in abstract.
-
Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes.Animalssize not reportedAnimal study of a KEDWa tetrapeptide analog
In rats with alloxan-induced diabetes, the KEDW tetrapeptide partially restored insulin synthesis and produced a glucose curve similar to that of normal animals.
Study details
- Studied
- Rats with alloxan-induced diabetes
- Main outcome
- Insulin synthesis and sugar curve
- Authors' conclusion
- The tetrapeptide partially restored insulin synthesis and gave a sugar curve slope similar to normal animals; a promoter-binding mechanism is proposed (presumed).
- Limitations
- Animal study; mechanism is presumptive.
-
Effects of pancragen on the differentiation of pancreatic cells during their ageing.Cells / labIn vitro expression study
In cultured human pancreatic cells, pancragen increased expression of acinar and islet differentiation factors (Pdx1, Pax6, Pax4, Foxa2 and others), with a larger effect in aged cultures.
Study details
- Studied
- Young and aged pancreatic cell cultures
- Main outcome
- Expression of acinar and islet differentiation factors
- Authors' conclusion
- Pancragen stimulated expression of differentiation factors (e.g. Pdx1, Pax6, Foxa2) in young and aged cultures; transcription factors are proposed as its pharmacological target.
- Limitations
- In vitro only.
-
[Tetrapeptide stimulates functional activity of the pancreatic cells in aging].Cells / labIn vitro expression study
In aged human pancreatic cell cultures, the tetrapeptide raised proliferation and anti-apoptotic markers (PCNA, Ki67, Mcl1) and lowered p53.
Study details
- Studied
- Aged human pancreatic cell cultures
- Main outcome
- Expression of functional, proliferation and apoptosis markers
- Authors' conclusion
- The tetrapeptide increased MMP2, MMP9, serotonin, CD79alpha, Mcl1, PCNA and Ki67 and decreased p53 expression in aged pancreatic cells.
- Limitations
- In vitro only.
-
Peptides tissue-specifically stimulate cell differentiation during their aging.Cells / labIn vitro expression study in young and late-passage (aging) cultures
In aging human cell cultures, pancragen raised differentiation-factor expression in pancreatic cells specifically, while other short peptides acted on bronchial or prostatic cells.
Study details
- Studied
- Human embryonic pancreatic and bronchial cells and prostatic fibroblasts in culture
- Main outcome
- Expression of CXCL12, Hoxa3 and WEGC1 differentiation factors
- Authors' conclusion
- Vesugen stimulated differentiation factor expression in fibroblasts, with a stronger effect in aged cultures, which may be a mechanism of geroprotective effect.
- Limitations
- In vitro cell culture only.
-
Effect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus.Animalssize not reportedAnimal experiment; control details not stated in the abstract
In rats with experimental diabetes, Pancragen was reported to improve pancreatic tissue morphology and function (developer's institute; abstract gives no numbers).
Study details
- Studied
- Rats with experimental diabetes mellitus
- Main outcome
- Morphology and function of pancreatic tissue
- Authors' conclusion
- The authors report a regulatory effect of Pancragen on pancreatic morphology and function in diabetic rats and see good prospects for the drug.
- Limitations
- Animal study; abstract gives no sample size, controls or effect sizes.
-
Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells.Cells / labIn vitro gene expression and promoter DNA-methylation analysis with KEDW and AEDL peptides
In aging human pancreatic and bronchial cell cultures, the peptide KEDW (Pancragen) tissue-specifically changed expression of pancreatic genes (PDX1, PAX6, NGN3) alongside promoter methylation changes; a mechanism study with no clinical outcome.
Study details
- Studied
- Ageing human pancreatic and bronchial epithelium cell cultures
- Compared with
- Untreated cultures of different age
- Main outcome
- Gene expression and promoter methylation of PDX1, PAX6, NGN3 and other genes
- Authors' conclusion
- Changes in promoter methylation might explain the age- and peptide-induced changes in expression of PDX1, PAX6 and NGN3 in pancreatic cells; other genes appear controlled by other mechanisms.
- Limitations
- Cell cultures only; mechanism, not efficacy.
Reported side effects
The single human report (33 patients) was uncontrolled and did not report adverse events, so there is essentially no human safety data.
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Discussions elsewhere
Experiences and questions about Pancragen on other sites. Treat anecdotes with care.
Pancragen: questions people ask
What is Pancragen?
Russian short-peptide bioregulator. One of the Khavinson "bioregulator" peptides from Russian aging research, marketed for the pancreas. Evidence comes mainly from Russian cell and animal studies.
How much does Pancragen cost?
The cheapest Pancragen from an independently tested vendor is $0.475 per mg (Andy Peps Studio, PA20 Pancragen 20mg * 10 vials, $95.00). Across 14 listings from 13 vendors the median is $2.05 per mg.
Where can I buy Pancragen?
13 vendors tested by Finnrick sell Pancragen. The cheapest per mg right now: Andy Peps Studio ($0.475), Baohua Dongnuo Biotechnology BHD ($0.475), LN Peptides ($0.475). 0 of them publish a lab report (COA) for Pancragen; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 20 mg of Pancragen?
Adding 2 mL of bacteriostatic water to a 20 mg vial of Pancragen gives 10 mg/mL: each 10 units on a U-100 insulin syringe holds 1,000 mcg. With 1 mL it's 20 mg/mL (2,000 mcg per 10 units); with 3 mL, 6.667 mg/mL (666.7 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 20 mg.
Is Pancragen FDA approved?
Sold as a supplement in Russia; not approved in the US. Research use only.
Can Pancragen be compounded in the US?
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Compounding status for every peptide.
Does Pancragen work? What does the research say?
Evidence grade C (mostly animal studies), from 10 papers: Only one small non-randomized, non-placebo human study from the developer's group; the controlled data are in rats, aged monkeys and cell cultures. Pancragen (the tetrapeptide Lys-Glu-Asp-Trp) has been studied almost entirely by one Russian research group, mostly in rats, aged monkeys and cell culture, where it lowers blood glucose and stimulates pancreatic cell markers. The only human report is a small non-randomized, non-placebo-controlled study in elderly people with type 2 diabetes; no independent or randomized human data were found. See the papers.
What dose of Pancragen was used in studies?
Pancragen is tested only in animals or cells. Old female rhesus monkeys received 0.05 mg (50 mcg) per animal per day intramuscularly for 10 days (PMIDs 28509500, 25946840); diabetic rats received it by mouth or intramuscularly (dose not stated); tissue cultures used 0.05 ng/ml. These are amounts used in published studies or official labels, not a recommendation.